Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Specials
Spring Home & Garden Show
Home & Realty
Outdoor Guide
Women
Spring on the Road
Spring Wellness
Premier Home Stylle Tour 2024
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
2024 Readersâ Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Mirum Pharmaceuticals Inc
(NQ:
MIRM
)
43.11
+1.13 (+2.69%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Mirum Pharmaceuticals Inc
< Previous
1
2
3
4
5
6
7
8
9
Next >
11 Analysts Have This to Say About Mirum Pharmaceuticals
November 20, 2023
Via
Benzinga
Mirum Pharmaceuticals Presents New Data at The Liver Meeting®
November 13, 2023
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 10, 2023
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Analyst Ratings for Mirum Pharmaceuticals
November 03, 2023
Via
Benzinga
Mirum Pharmaceuticals to Present at the 2023 UBS Biopharma Conference
November 03, 2023
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Earnings Outlook For Mirum Pharmaceuticals
November 01, 2023
Via
Benzinga
Analyst Ratings for Mirum Pharmaceuticals
October 09, 2023
Via
Benzinga
Mirum Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update
November 02, 2023
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Mirum Pharmaceuticals to Present New Data at The Liver Meeting®
October 30, 2023
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Mirum Pharmaceuticals to Announce Third Quarter 2023 Financial Results and Host Conference Call on November 2, 2023
October 27, 2023
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Mirum Pharmaceuticals Announces New PDUFA Date for LIVMARLI for the Treatment of Cholestatic Pruritus in Progressive Familial Intrahepatic Cholestasis
October 17, 2023
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Analyst Ratings for Mirum Pharmaceuticals
September 13, 2023
Via
Benzinga
Where Mirum Pharmaceuticals Stands With Analysts
August 21, 2023
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 24, 2023
October 24, 2023
Via
Benzinga
7 Small-Cap Stocks That Get the Nod from Wall Street
October 11, 2023
Although small-cap stocks tend to be extremely risky, these compelling ideas just happen to get the nod from Wall Street analysts.
Via
InvestorPlace
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 10, 2023
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Mirum Pharmaceuticals Presents LIVMARLI Clinical Data and Real-World Evidence at NASPGHAN
October 07, 2023
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Mirum Pharmaceuticals Announces Positive Phase 3 RESTORE Study Results Evaluating Chenodal in Patients with Cerebrotendinous Xanthomatosis
October 02, 2023
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Mirum Pharmaceuticals to Highlight LIVMARLI Data from its ALGS and PFIC Programs at the NASPGHAN Annual Meeting
September 26, 2023
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Why Shares of Travere Therapeutics Are Slumping Thursday
September 21, 2023
A mixed trial could hurt a kidney drug's chances of full approval.
Via
The Motley Fool
Mirum Pharmaceuticals to Present at the 2023 Cantor Global Healthcare Conference
September 21, 2023
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For September 20, 2023
September 20, 2023
Via
Benzinga
Mirum Pharmaceuticals Announces the Appointment of Eric Bjerkholt as Chief Financial Officer
September 11, 2023
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 08, 2023
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
September 06, 2023
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Around $4M Bet On This Healthcare Stock? Check Out These 3 Stocks Insiders Are Buying
September 06, 2023
Although U.S. stocks closed mostly lower on Tuesday, there were a few notable insider trades.
Via
Benzinga
Mirum Pharmaceuticals Completes Acquisition of Bile Acid Product Portfolio for Treatment of Rare Liver Diseases from Travere Therapeutics
September 05, 2023
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Travere Therapeutics Completes Sale of Bile Acid Product Portfolio to Mirum Pharmaceuticals
September 05, 2023
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 10, 2023
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Mirum Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Update
August 03, 2023
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.